Literature DB >> 31061000

Long-term Survival after resection for perihilar cholangiocarcinoma: Impact of UICC staging and surgical procedure.

Benjamin Juntermanns1, Gernot Maximillian Kaiser2, Henning Reis3, Silvia Gries1, Stefan Kasper4, Andreas Paul1, Ali Canbay5, Christian Dominik Fingas1.   

Abstract

BACKGROUND/AIMS: Perihilar cholangiocarcinoma is a rare disease with unfavorable prognosis resulting in low survival rates. This study aims to retrospectively assess the beneficial histopathological features and surgical procedures in long-term survivors (i.e., patients surviving perihilar cholangiocarcinoma for at least 2 y).
MATERIAL AND METHODS: In total, 322 patients with perihilar cholangiocarcinoma underwent surgery at our center. The follow-up ended in 2017; 76 patients survived for >2 y. The type of resection, UICC stage, and histopathological features were compared between three survival groups (>2-3, >3-5, and >5 y).
RESULTS: The >5-year-survival rate in our selected study cohort was 43.4% (>3-5 y,31.6% and >2-3 y, 25.0%), and 14.5% of the patients survived for >10 y after surgery. Patients with non-regional lymph node positive tumors and/or distant metastasis (i.e., UICC stage IVb; p=0.0112), R2 status (p=0.0288), and exploratory laparotomy only (p=0.0157) showed the poorest survival rates. Perineural invasion had no significant impact on the overall survival. However, 29.0% patients surviving for >5 y displayed the lowest perineural infiltration prevalence. Interestingly, Bismuth-Corlette stage IIIa (p=0.0467), especially caudate lobectomy (p=0.0034), was associated with disease-specific overall survival of >5y.
CONCLUSION: Complete/extended tumor resection with additional caudate lobe resection is strongly associated with long-term survival. Perineural infiltration as a negative prognostic marker for prolonged survival needs to be evaluated in larger study cohorts.

Entities:  

Mesh:

Year:  2019        PMID: 31061000      PMCID: PMC6505650          DOI: 10.5152/tjg.2019.18275

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  18 in total

1.  Surgery for hilar cholangiocarcinoma: an Italian experience.

Authors:  G M Gazzaniga; M Filauro; C Bagarolo; L Mori
Journal:  J Hepatobiliary Pancreat Surg       Date:  2000

2.  Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis.

Authors:  Tamara Z Vern-Gross; Anand T Shivnani; Ke Chen; Christopher M Lee; Jonathan D Tward; O Kenneth MacDonald; Christopher H Crane; Mark S Talamonti; Louis L Munoz; William Small
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-23       Impact factor: 7.038

3.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

4.  Radical resection of hilar bile duct carcinoma and predictors of survival.

Authors:  T Todoroki; T Kawamoto; N Koike; H Takahashi; S Yoshida; H Kashiwagi; Y Takada; M Otsuka; K Fukao
Journal:  Br J Surg       Date:  2000-03       Impact factor: 6.939

5.  Surgical treatment for hilar cholangiocarcinoma.

Authors:  M Tabata; Y Kawarada; H Yokoi; T Higashiguchi; S Isaji
Journal:  J Hepatobiliary Pancreat Surg       Date:  2000

6.  Prognostic assessment of three single-nucleotide polymorphisms (GNB3 825C>T, BCL2-938C>A, MCL1-386C>G) in extrahepatic cholangiocarcinoma.

Authors:  Christian Dominik Fingas; Antonios Katsounas; Alisan Kahraman; Winfried Siffert; Christoph Jochum; Guido Gerken; Holger Nückel; Ali Canbay
Journal:  Cancer Invest       Date:  2010-06       Impact factor: 2.176

7.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

8.  Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT.

Authors:  Jun Li; Hilmar Kuehl; Florian Grabellus; Stephan P Müller; Sonia Radunz; Gerald Antoch; Silvio Nadalin; Christoph E Broelsch; Guido Gerken; Andreas Paul; Gernot M Kaiser
Journal:  J Surg Oncol       Date:  2008-11-01       Impact factor: 3.454

Review 9.  Hilar cholangiocarcinoma: current management.

Authors:  Fumito Ito; Clifford S Cho; Layton F Rikkers; Sharon M Weber
Journal:  Ann Surg       Date:  2009-08       Impact factor: 12.969

10.  Cholangiocellular carcinoma--the role of caudate lobe resection and mesohepatectomy.

Authors:  Massimo Malago; Andrea Frilling; Jun Li; Hauke Lang; Christoph E Broelsch
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

View more
  2 in total

1.  Surgical outcomes of perihilar cholangiocarcinoma based on the learning curve of a single surgeon at a tertiary academic hospital: A retrospective study.

Authors:  Hye Jeong Park; Dai Hoon Han; Gi Hong Choi; Jin Sub Choi
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-02-28

2.  Modification of the eighth AJCC/UICC staging system for perihilar cholangiocarcinoma: An alternative pathological staging system from cholangiocarcinoma-prevalent Northeast Thailand.

Authors:  Chaiwat Aphivatanasiri; Prakasit Sa-Ngiamwibool; Sakkarn Sangkhamanon; Piyapharom Intarawichian; Waritta Kunprom; Malinee Thanee; Piya Prajumwongs; Narong Khuntikeo; Attapol Titapun; Apiwat Jareanrat; Vasin Thanasukarn; Tharatip Srisuk; Vor Luvira; Kulyada Eurboonyanun; Julaluck Promsorn; Watcharin Loilome; Aileen Wee; Supinda Koonmee
Journal:  Front Med (Lausanne)       Date:  2022-09-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.